Please login to the form below

Not currently logged in
Email:
Password:

RVT-602

This page shows the latest RVT-602 news and features for those working in and with pharma, biotech and healthcare.

Takeda forms new women's health and cancer company

Takeda forms new women's health and cancer company

Myovant has also received an exclusive, commercial license for RVT-602, Takeda's oligopeptide kisspeptin receptor agonist for the treatment of female infertility.

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Thrive Agency

We are a specialist health communication agency creating powerful and trusted content. If you’re looking for a partner to help...

Latest intelligence

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
...
New Playbook Alert: Virtual Patient Engagement
...
Millennials: the wellness generation
Looking at the results from a global healthcare research study focusing on the patients of the future...